Study: Rushing FDA approvals might compromise drug safety

Harvard University researchers found drugs the FDA cleared shortly before its deadline are more prone to safety problems than those approved with time to spare. The FDA said it does not grant approval unless it is ready. It "has the option of denying approval altogether if there is any question about safety," said Janet Woodcock, head of the agency's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal (free content), The · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC